Jonathan Tegge
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Jonathan Tegge
Jonathan Tegge was last confirmed as CFO at InMed Pharmaceuticals Inc. (INM) in a filing dated October 28, 2024. Earlier roles on record: CFO at InMed Pharmaceuticals Inc. (INM) until February 20, 2024. InMed Pharmaceuticals Inc. reported in an 8-K filed February 9, 2024 that Jonathan Tegge resigned as Interim Chief Financial Officer, effective February 20, 2024. InMed Pharmaceuticals Inc. reported in an 8-K filed December 13, 2022 that Jonathan Tegge was appointed Interim Chief Financial Officer, effective December 12, 2022.
“Mr. Tegge will cease, pursuant to the terms of his resignation delivered to the Company on February 8, 2024, to serve as the Company's Interim Chief Financial Officer (and likewise, as the Company's principal financial officer and principal accounting officer) immediately preceding the Effective Date and upon Ms. Jagpal's appointment as Chief Financial Officer and Corporate Secretary.”
“As described above, the Company appointed Mr. Tegge as Interim Chief Financial Officer of the Company effective December 12, 2022.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2024-10-28
Last confirmed by a filing; no departure on record
-
Start not stated–2024-02-20
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.